Evidence map›Paper›PMID 42400907›Full record

ArticleCell reports2026

RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer.

Omar Lujano-Olazaba, Mikella Robinson, Gregory J Jordan, Sofia Howe, Anna Platen, Cassidy Lucht, Dishant Vandra, Cecilia Gallo, Mena Shammas, Katelyn Shelby and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Omar Lujano-OlazabaDepartment of Biology, San Diego State University, San Diego, CA 92182, USA.
Mikella RobinsonDepartment of Biology, San Diego State University, San Diego, CA 92182, USA.
Gregory J JordanDepartment of Biology, San Diego State University, San Diego, CA 92182, USA.
Sofia HoweDepartment of Biology, San Diego State University, San Diego, CA 92182, USA.
Anna PlatenDepartment of Molecular Medicine, University of Regensburg, 93053 Regensburg, Germany.
Cassidy LuchtDepartment of Biology, San Diego State University, San Diego, CA 92182, USA.
Dishant VandraDepartment of Biology, San Diego State University, San Diego, CA 92182, USA.
Cecilia GalloDepartment of Biology, San Diego State University, San Diego, CA 92182, USA.
Mena ShammasDepartment of Biology, San Diego State University, San Diego, CA 92182, USA.
Katelyn ShelbyDepartment of Biology, San Diego State University, San Diego, CA 92182, USA.
Nathan WongAdvanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; CCR Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Ingrid R NiesmanElectron Microscope Facility, San Diego State University, San Diego, CA 92182, USA.
David D SchlaepferMoores Cancer Center, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, San Diego, La Jolla, CA 92037, USA.
David A ChereshMoores Cancer Center, Department of Pathology, and Sanford Consortium for Regenerative Medicine at the University of California, San Diego, San Diego, La Jolla, CA 92037, USA.
Christina M AnnunziataNational Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Carrie D HouseDepartment of Biology, San Diego State University, San Diego, CA 92182, USA; Moores Cancer Center, Cancer Biology and Signaling Program, University of California, San Diego, San Diego, La Jolla, CA 92037, USA. Electronic address: cdhouse@sdsu.edu.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
TALENT Shared Resources CoreU54CA285115 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI James D Murphy · 2023 to 2026
$6.6M
Research Education CoreU54CA285117 · NCI · SAN DIEGO STATE UNIVERSITY · PI Richard Matthew Cripps, MARIA ELENA MARTINEZ · 2023 to 2026
$6.2M
Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapseR01CA260281 · NCI · SAN DIEGO STATE UNIVERSITY · PI Carrie Danielle House · 2022 to 2026
$2.1M
Role of NF-kB signaling in supporting ovarian cancer tumor-initiating cells responsible for cancer recurrenceR00CA204727 · NCI · SAN DIEGO STATE UNIVERSITY · PI HOUSE, CARRIE DANIELLE · 2018 to 2020
$861k
NCI NIH HHS R00 CA204727NCI NIH HHS R01 CA260281NCI NIH HHS U54 CA285115NCI NIH HHS U54 CA285117NIH HHS 75N91019D00024
6 · The paper itself

Abstract

High-grade serous ovarian cancer (HGSOC) often relapses after chemotherapy due to chemoresistant cancer stem-like cells (CSCs). NF-κB signaling, previously shown to enhance stemness traits, was investigated for its role in post-treatment tumor regrowth. Here, we found that NF-κB subunits RelA and RelB jointly regulate extracellular matrix genes but differentially control integrin subunits: RelA regulates ITGAV (αV) and RelB regulates ITGB3 (β3). Integrin αVβ3 expression is upregulated on CSCs, and this is partially driven by NF-κB activation. In vivo models demonstrate that αVβ3

Indexed as

Integrin alphaVbeta3Neoplasm Recurrence, LocalOvarian NeoplasmsStress, PhysiologicalTranscription Factor RelBAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceNeoplastic Stem CellsSignal TransductionTranscription Factor RelAIntegrin alphaVbeta3RELB protein, humanTranscription Factor RelATranscription Factor RelBcancer stem-like cellCP: cancerintegrinsmetastasisNF-κBovarian cancerstress toleranceαVβ3

Identifiers

PMID42400907
PMCPMC13464571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.